ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,815 | -13.0% | 375 | 0.0% | 0.00% | – |
| Q2 2023 | $8,981 | +27.3% | 375 | 0.0% | 0.00% | – |
| Q1 2023 | $7,057 | +18.2% | 375 | 0.0% | 0.00% | – |
| Q4 2022 | $5,970 | -0.5% | 375 | 0.0% | 0.00% | – |
| Q3 2022 | $6,000 | +20.0% | 375 | 0.0% | 0.00% | – |
| Q2 2022 | $5,000 | -44.4% | 375 | 0.0% | 0.00% | – |
| Q1 2022 | $9,000 | +12.5% | 375 | 0.0% | 0.00% | – |
| Q4 2021 | $8,000 | +33.3% | 375 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | -33.3% | 375 | 0.0% | 0.00% | – |
| Q2 2021 | $9,000 | 0.0% | 375 | 0.0% | 0.00% | – |
| Q1 2021 | $9,000 | -55.0% | 375 | 0.0% | 0.00% | – |
| Q4 2020 | $20,000 | +33.3% | 375 | 0.0% | 0.00% | – |
| Q3 2020 | $15,000 | -16.7% | 375 | 0.0% | 0.00% | – |
| Q2 2020 | $18,000 | +20.0% | 375 | 0.0% | 0.00% | – |
| Q1 2020 | $15,000 | +114.3% | 375 | +100.5% | 0.00% | – |
| Q4 2019 | $7,000 | +16.7% | 187 | 0.0% | 0.00% | – |
| Q3 2019 | $6,000 | +50.0% | 187 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | – | 187 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |